P-ISSN 2587-2400 | E-ISSN 2587-196X
Ejmo Kapak
EJMO Volume : 8 Issue : 3 Year : 2024
COVID-19 in EJMO 8/3EJMO Current Issue EJMO Archive EJMO & Congress Most Cited Articles Ahead of Print
Copyright Transfer Form
ICMJE COI Form

Volume: 6 Issue: 1 - 2022

REVIEW
Immunotherapy for Cancer: Strategies of Immunomodulation Therapy in Combination with Conventional Approaches
Tanvi Gupta, Mohd Murtaza, Mrinmoy Ghosh, Wen Pin Su, Narendra Kumar Pandey, Umesh Goutam
doi: 10.14744/ejmo.2022.51601   Pages  1 -  11 
(Viewed: 105111)
Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers
Senem Karabulut, Meltem Topalgokceli Selam, Didem Tastekin
doi: 10.14744/ejmo.2022.74316   Pages  12 -  15 
(Viewed: 35302)
Wnt signaling and plasticity of lung cancer cells
Anna Michele Tornatore, Juan Sebastian Yakisich
doi: 10.14744/ejmo.2022.31979   Pages  16 -  24 
(Viewed: 3770)
RESEARCH ARTICLE
Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma
Yu-Xian Teng, Ping-Ping Guo, Ke-Zhang Qin, Kang Chen, George Papatheodoridis, Bang-De Xiang, Liang Ma, Jian-Hong Zhong
doi: 10.14744/ejmo.2022.25618   Pages  25 -  29 
(Viewed: 109078)
Importance of Diagnosis in Breast Cancer with Non-BRCA Pathogenic Germline Variants of Cancer Susceptibility Genes using High-Throughput Sequencing Analysis
Akif Ayaz, Sinem Yalcintepe, Serhat Seyhan, Fazli Cem Gezen
doi: 10.14744/ejmo.2022.88057   Pages  30 -  42 
(Viewed: 1941)
Molecular Profile of Cutaneous Melanoma
Natalia N. Mazurenko, Irina V. Tsyganova, Irina N. Mikhailova, Olga A. Anurova, Lev V. Demidov, Anna A. Lushnikova
doi: 10.14744/ejmo.2022.34002   Pages  43 -  49 
(Viewed: 3236)
Analysis of Bloodstream Infections and Their Antibiotic Sensitivity Pattern (Pre- and Post-COVID Lockdown in an Indian Cancer Hospital): A Record-Based Retrospective Cohort Study
Vinod K. Ramani, Somorat Bhattacharjee, Shobha Ganeshan, Radheshyam Naik
doi: 10.14744/ejmo.2022.18855   Pages  50 -  58 
(Viewed: 3140)
Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
Hasan Cagri Yildirim, Deniz Can Guven, Oktay Halit Aktepe, Hakan Taban, Feride Yilmaz, Serkan Yasar
doi: 10.14744/ejmo.2022.78280   Pages  59 -  63 
(Viewed: 3443)
GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients
Rajaa Benzeid, Amina Gihbid, Nadia Benchekroun, Karima Bendahhou, Naima El Benna, Amal Guensi, Imane Chaoui
doi: 10.14744/ejmo.2022.89238   Pages  64 -  72 
(Viewed: 3017)
A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic
Mohsen Gholi-Nataj, Shahab Rafieian, Maedeh Barahman, Ahmad Shirinzadeh-Dastgiri, Mohammad Vakili, Reza Ershadi
doi: 10.14744/ejmo.2022.50535   Pages  73 -  82 
(Viewed: 3285)
Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives
Mostafa Davoodabadi-Farahani, Yaser Mansoori, Shahrzad Ilbeigi, Maedeh Barahman, Mohsen Mazloomrezaei, Pouria Khani, Seyed MohamMadbagher Tabei, Seyed Alireza Dastgheib, Hossein Neamatzadeh
doi: 10.14744/ejmo.2022.33174   Pages  83 -  88 
(Viewed: 3141)
CASE REPORT
Sarcoid Like Reactıon Mimicking Disease Progression Associated With Nivolumab in A Case Wıth Malignant Mesothelıoma: Is There a Solution For This Dilemma
Semra Paydas, Ilhan Tuncer, Ahmet Baris Guzel, Cem Kaan Parsak, Isa Burak Guney
doi: 10.14744/ejmo.2022.91216   Pages  89 -  91 
(Viewed: 2820)
LETTER TO THE EDITOR
Sarcomatoid Chromophobe Renal Cell Carcinoma
José-Fernando Val-Bernal, José-Javier Gómez-Román, Marta-María Mayorga-Fernández
doi: 10.14744/ejmo.2022.75565   Pages  92 -  93 
(Viewed: 1871)

Submit Manuscript
WEB OF SCIENCE click

  • Impact Factor: 2.5

  • Medicine, General & Internal: Q2 146/322


    • SCOPUS click

  • CiteScoreTracker 2023: 3.6
  • CiteScore year 2022:
    0.9
  • CiteScore year 2021:
    0.2


    • Google Scholar click

  • Number of Articles:315
  • Citations:2587
  • h-index:16
  • i10-index:=26

  • EJMO NLM ID: 101720527

  • Accept Ratio :18.2 %
  • Final decision avg 34 day

    • Copyright © 2024 Eurasian Journal of Medicine and Oncology, EJMO

    EJMO & EJMO